Literature DB >> 3949982

Irreversible binding of zomepirac to plasma protein in vitro and in vivo.

P C Smith, A F McDonagh, L Z Benet.   

Abstract

Zomepirac is a nonsteroidal anti-inflammatory drug recently withdrawn from use because of an unexplained high incidence of immunological reactions. It is metabolized in humans to a reactive, unstable acyl glucuronide which accumulates in plasma. Because of the similarity of zomepirac glucuronide to bilirubin glucuronide in structure and stability and the documented irreversible binding of bilirubin to albumin through its acyl glucuronide, we studied the reaction of zomepirac acyl glucuronide with albumin in vitro from pH 5 to 9 and in vivo in six healthy human volunteers who had received a single 100-mg oral dose of zomepirac. Irreversible binding of zomepirac to protein was determined by exhaustive washing of protein, followed by hydrolysis of bound zomepirac-protein adduct with base, extraction of the liberated drug, and chromatographic measurement. Irreversible binding was observed both in vitro and in vivo. The extent of binding in vitro was time- and pH-dependent. In vitro drug binding was also observed for the isomers of zomepirac glucuronide which were formed by intramolecular acyl migration. Irreversible binding in vivo correlated with overall exposure to zomepirac glucuronide when exposure was expressed as the area under the plasma concentration vs. time curve. When probenecid (500 mg, twice daily), which decreases the plasma clearance of zomepirac glucuronide, was administered concurrently with zomepirac, irreversible binding of zomepirac was increased. The nature of the zomepirac protein binding is probably covalent. Formation of irreversibly protein-bound zomepirac occurs via the acyl glucuronide as previously shown for bilirubin glucuronide, and the reaction may be general for other drugs that are metabolized to acyl glucuronides.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3949982      PMCID: PMC423485          DOI: 10.1172/JCI112392

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Acylation of albumin by 1-O-acyl glucuronides.

Authors:  R B van Breemen; C Fenselau
Journal:  Drug Metab Dispos       Date:  1985 May-Jun       Impact factor: 3.922

2.  Simultaneous determination of zomepirac and its major metabolite zomepirac glucuronide in human plasma and urine.

Authors:  P N Langendijk; P C Smith; J Hasegawa; L Z Benet
Journal:  J Chromatogr       Date:  1984-05-11

3.  The nature of four bilirubin fractions from serum and of three bilirubin fractions from bile.

Authors:  C C Kuenzle; C Maier; J R Rüttner
Journal:  J Lab Clin Med       Date:  1966-02

4.  Apparent anaphylactic reaction to zomepirac (Zomax)

Authors:  S A Samuel
Journal:  N Engl J Med       Date:  1981-04-16       Impact factor: 91.245

5.  Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac.

Authors:  P C Smith; P N Langendijk; J A Bosso; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

6.  Separation of bilirubin species in serum and bile by high-performance reversed-phase liquid chromatography.

Authors:  J J Lauff; M E Kasper; R T Ambrose
Journal:  J Chromatogr       Date:  1981-12-11

7.  Origin of mammalian biliprotein and rearrangement of bilirubin glucuronides in vivo in the rat.

Authors:  A F McDonagh; L A Palma; J J Lauff; T W Wu
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

8.  Kinetic analysis of the nonenzymatic glycosylation of hemoglobin.

Authors:  P J Higgins; H F Bunn
Journal:  J Biol Chem       Date:  1981-05-25       Impact factor: 5.157

9.  The glycosylation of hemoglobin: relevance to diabetes mellitus.

Authors:  H F Bunn; K H Gabbay; P M Gallop
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

10.  Structure of carbohydrate of hemoglobin AIc.

Authors:  R J Koenig; S H Blobstein; A Cerami
Journal:  J Biol Chem       Date:  1977-05-10       Impact factor: 5.157

View more
  14 in total

Review 1.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

Review 2.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Reaction of acyl glucuronides with insulin in vitro: identification of an imine mechanism by electrospray ionization mass spectrometry.

Authors:  J H Liu; C D Marquez; S T Weintraub; P C Smith
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

Review 4.  Chirality and nonsteroidal anti-inflammatory drugs.

Authors:  P J Hayball
Journal:  Drugs       Date:  1996       Impact factor: 9.546

5.  Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!

Authors:  David E Smith; Malcolm Rowland; Kathleen M Giacomini; Gordon L Amidon
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

Review 6.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

7.  Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry.

Authors:  A Ding; J C Ojingwa; A F McDonagh; A L Burlingame; L Z Benet
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma.

Authors:  J C Ojingwa; H Spahn-Langguth; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

Review 9.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

Review 10.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.